Natural Supplements for COVID-19—Background, Rationale, and Clinical Trials

Melody Hermel, MD1,2, Megan Sweeney, MPH1,2, Yu-Ming Ni, MD1,2, Robert Bonakdar, MD2, Douglas Triffon, MD1,2, Christopher Suhar, MD1,2, Sandeep Mehta, MD1,2, Sarah Dalhoumi, MD2, and James Gray, MD1,2

Abstract
Worldwide, the turmoil of the SARS-CoV-2 (COVID-19) pandemic has generated a burst of research efforts in search of effective prevention and treatment modalities. Current recommendations on natural supplements arise from mostly anecdotal evidence in other viral infections and expert opinion, and many clinical trials are ongoing. Here the authors review the evidence and rationale for the use of natural supplements for prevention and treatment of COVID-19, including those with potential benefit and those with potential harms. Specifically, the authors review probiotics, dietary patterns, micronutrients, antioxidants, polyphenols, melatonin, and cannabinoids. Authors critically evaluated and summarized the biomedical literature published in peer-reviewed journals, preprint servers, and current guidelines recommended by expert scientific governing bodies. Ongoing and future trials registered on clinicaltrials.gov were also recorded, appraised, and considered in conjunction with the literature findings. In light of the controversial issues surrounding the manufacturing and marketing of natural supplements and limited scientific evidence available, the authors assessed the available data and present this review to equip clinicians with the necessary information regarding the evidence for and potential harms of usage to promote open discussions with patients who are considering dietary supplements to prevent and treat COVID-19.

Keywords
ascorbic acid, micronutrients, niacinamide

Received October 3, 2020. Received revised March 17, 2021. Accepted for publication May 30, 2021.

Background
We are in an era that needs no introduction. The emergence of a novel coronavirus from Wuhan, China, at the end of 2019 has now become a worldwide pandemic, leading to significant research efforts in search of effective prevention and treatment modalities. Recently, remdesivir became the first approved treatment for severe COVID-19 infection1 and several vaccines were approved for emergency use, and are rapidly being deployed to protect vulnerable populations.2,3 Many medical therapies are being evaluated as treatment modalities for COVID-19; however, deliberative study of biochemical pathways, clinical efficacy, and safety profiles of various potential therapies cannot match the urgency of the ongoing pandemic. Additionally, prevention of COVID-19 thus far has focused on public health efforts such as handwashing and mask-wearing as well as vaccination, and therapies are lacking.

In the meantime, patients have turned their attention to natural supplements in search of preventive and therapeutic options.4,5 Nutritional and dietary supplements (nutraceuticals) are utilized regularly by approximately half of the US population and intermittently used by an estimated 3-quarters of the US population.4 Despite this statistic, only a third of patients disclose the use of nutraceuticals in clinical encounters.6 The COVID-19 pandemic has heralded a surge in sales of certain supplements by over 400%, in spite of a dearth of studies.
examining supplements and COVID-19. The majority of evidence supporting use of natural supplements for COVID-19 is presumptive based on previous research into other viral conditions such as coronaviruses and respiratory complications seen in COVID-19. Additionally, variability in product quality underscores the important of safety and regulation of supplements purported to prevent or treat COVID-19, for which many resources are available but underutilized.

This review examines current literature and registered clinical trials to determine which supplements have promise for treatment and prevention of COVID-19 and which supplements are potentially harmful. The authors do not explicitly encourage use of any individual nutraceutical for COVID-19 prevention or treatment; rather, this review serves to inform practitioners interested in recommending or prescribing these supplements.

Materials and Methods

This comprehensive review encompasses original research articles, viewpoints, critiques, proposals, guidelines, and registered trials in which vitamins and supplements are discussed in the context of the novel coronavirus (SARS-CoV-2) that causes COVID-19. From March 15th, 2020, through March 3rd, 2021, the authors conducted weekly environmental scans, critically evaluated, and summarized the biomedical literature published in peer-reviewed journals, preprint servers, and current guidelines recommended by expert scientific governing bodies. Ongoing and future trials registered on clinicaltrials.gov, the official clinical research study registry run by the United States National Library of Medicine and National Institutes of Health, were also recorded, appraised, and considered in conjunction with the literature findings.

Microbial Dysbiosis and Probiotics

Much attention has been paid to the role of the microbiome on immune health, and the therapeutic effects of probiotic supplementation (Table 1). Microbial dysbiosis combined with a pro-inflammatory diet, such as the standard Western diet, can lead to a breakdown of gut integrity and subsequent translocation of commensal bacteria and their metabolites into the peripheral circulation. Consequently, this leads to systemic inflammation and impairs adaptive immunity while potentiating innate immunity. Thus, microbial dysbiosis has impacts on immune health beyond the gut. As a result, probiotics have been extensively studied for their role in local as well as systemic immunity. Various strains of probiotics show promise for protecting against Clostridium difficile infection as well as ICU-related microbial dysbiosis. Moreover, probiotics modulate systemic immunity to reduce the inflammatory response while upregulating antiviral actions via stimulation of native immunity in the gut, thereby contributing to improved outcomes in upper respiratory and lower respiratory infection. Prior studies have shown probiotics to shorten the duration of respiratory infections and reduce the frequency of ventilator-associated pneumonia. Lactobacillus plantarum in particular reduces upper respiratory infection symptoms and duration via an upregulation of immune cytokines and cellular response.

Given the broad effects of probiotics on inflammation, probiotics may prove useful in reducing the systemic inflammatory response in COVID-19. Recent publications suggest that COVID-19 may contribute to gut inflammation and subsequently microbial dysbiosis. This is evidenced by elevated levels of fecal calprotectin and serum IL-6, often seen in patients presenting clinically with diarrhea. COVID-19 also substantially detriments microbial flora by down-regulating ACE2 expression in infected cells. A small case series from China revealed microbial dysbiosis with decreased Lactobacillus and Bifidobacterium species in patients with COVID-19, and prior coronaviruses have also been associated with microbial dysbiosis. Together, these findings suggest that probiotics, particularly Lactobacillus species, may reduce both local gut inflammation and systemic inflammation seen in COVID-19.

Table 1. Probiotics and COVID-19.

| Probiotics | Mechanism of action and potential benefits | Potential harms or adverse reactions | Association with COVID-19 infection | Ongoing registered clinical trials related to COVID-19 |
|------------|------------------------------------------|------------------------------------|-----------------------------------|---------------------------------|
|            | Prevents gut dysbiosis and intestinal inflammation | May theoretically cause the following side effects in at risk patients with weakened immune system, gut dysbiosis and/or impaired intestinal barrier. | Downregulates ACE2 receptors, altering gut microbiota | There are 9 ongoing registered clinical trials related to probiotics and COVID19 on clinicaltrials.gov |
|            | Contributes to reduction in systemic inflammatory response |                                   | Upregulates pro-inflammatory chemokines and cytokines, including fecal calprotectin and serum interleukin-6 | |
|            | Improves outcomes in upper respiratory and lower respiratory infection |                                   | Microbial dysbiosis with decreased Lactobacillus and Bifidobacterium species in patients with COVID-19 | |
|            | Modulates antiviral activity via stimulation of native immunity in the gut |                                   |                                   | |

Given the broad effects of probiotics on inflammation, probiotics may prove useful in reducing the systemic inflammatory response in COVID-19. Recent publications suggest that COVID-19 may contribute to gut inflammation and subsequently microbial dysbiosis. This is evidenced by elevated levels of fecal calprotectin and serum IL-6, often seen in patients presenting clinically with diarrhea. COVID-19 also substantially detriments microbial flora by down-regulating ACE2 expression in infected cells. A small case series from China revealed microbial dysbiosis with decreased Lactobacillus and Bifidobacterium species in patients with COVID-19, and prior coronaviruses have also been associated with microbial dysbiosis. Together, these findings suggest that probiotics, particularly Lactobacillus species, may reduce both local gut inflammation and systemic inflammation seen in COVID-19.
There are currently 9 registered clinical trials exploring the use of probiotics as a therapeutic agent for COVID-19. In particular, one study is utilizing probiotics in healthcare workers to determine if they can decrease the incidence of healthcare-associated infections and gastrointestinal symptoms in patients with COVID-19. Other studies are using probiotics in combination with therapies (oxygen-ozone treatment, micronutrients) to potentially reduce the rate of intubation and length of hospitalization in patients with COVID-19. Caution is advised when administering probiotics to patients with immunosuppression or an impaired intestinal barrier due to chronic gastrointestinal illness such as inflammatory bowel disease. In patients with a weakened immune system, probiotics may be associated with systemic infections, altered metabolic function, excessive systemic immune response, and gene transfer. Otherwise, probiotics are generally well tolerated.

### Dietary Effects on COVID-19

The therapeutic effect of food cannot be understated when discussing COVID-19 prevention and treatment (Table 2). Appropriate nutrition is essential for a fully functional immune system and impacts infection risk from an early age. Both malnutrition from underconsumption or starvation and from

| Table 2. Dietary Patterns and COVID-19. |
|----------------------------------------|
| Mechanism of action and potential benefits | Potential harms or adverse reactions | Association with COVID-19 infection | Ongoing registered clinical trials related to COVID-19 |
| Mediterranean diet pattern | Western diet is pro-inflammatory by impairing adaptive immunity and host defense against viral infection | Overemphasis on the benefits of healthy diet may limit emphasis on exercise and the important social aspects of the Mediterranean diet | Worsened outcomes in obese patients | There are 5 registered clinical trials related to Mediterranean diet and COVID-19 on clinicaltrials.gov |
| Omega-3 FA supplementation | Reduces pro-inflammatory cytokines | Potential risk of increased bleeding | May improve clinical outcomes for patients with acute respiratory distress syndrome, a complication of COVID-19 infection | There are 10 registered clinical trials related to omega-3 fatty acid supplementation and COVID-19 on clinicaltrials.gov |

- Greater dietary fiber intake is associated with reduced risk of death from respiratory or infectious causes.
- Adiponectin, an anti-inflammatory chemokine, is higher in those consuming and adherent to Mediterranean diet.
- Adiponectin, an anti-inflammatory chemokine, is higher in those consuming and adherent to Mediterranean diet.
- Potential risk of increased bleeding.
- Association with atrial arrhythmias.
- Oxidation of Omega-3 FAs by reactive oxygen species may increase oxidative stress; co-treatment with antioxidants may mitigate this effect.
- There are 10 registered clinical trials related to omega-3 fatty acid supplementation and COVID-19 on clinicaltrials.gov.

- Omega-3 FAs attenuate inflammatory response in ARDS mouse and human models, though meta-analysis of human studies with nonsignificant effect.

- Omega-3 FAs reduce oxidative stress and may improve clinical outcomes for patients with acute respiratory distress syndrome, a complication of COVID-19 infection.
excess intake of foods of poor nutritional quality contribute to increased risk of infection. Inadequate protein and fiber intake contribute to risk of infection, as do micronutrient and antioxidant deficiencies. Moreover, malnutrition is highly prevalent in elderly patients with COVID-19. On the other hand, the Western diet, rich in fat and low in fiber and micronutrients, impairs the immune response to viral infection and may worsen risk of COVID-19. Obese patients who get COVID-19 are at higher risk for complications of the disease and may have higher mortality rates as well. Contributing to obesity is the weight gain and unhealthy eating patterns that have occurred as a consequence of the pandemic’s impact on daily life. Choosing a healthy diet, such as the Mediterranean diet, may help with reducing risk of infection via reducing inflammation and supporting immune system health. For example, adiponectin, an anti-inflammatory chemokine, is higher in those consuming and adherent to the Mediterranean diet. Multiple micronutrients and antioxidant compounds emphasized in this diet show promise for improving outcomes in COVID-19, and will be individually discussed below.

There are currently 5 registered trials looking at dietary patterns, including Mediterranean diet, and COVID-19. Adherence to a healthy diet is a significant barrier for some patients to achieve the proposed benefits, and effective counseling to help motivate patients is essential. Healthy diet is but one part of lifestyle management, and incorporation of dietary intervention into a comprehensive lifestyle intervention that addresses other aspects such as physical activity, mental health, social support, and healthcare access are essential for care of patients with COVID-19.

**Omega-3 Fatty Acids**

Omega-3 fatty acids function as active or precursor molecules on the anti-inflammatory cytokine production pathway. Omega-3 fatty acids have been associated with antioxidant and anti-inflammatory functions and may enhance antiviral responses via modulation of systemic immunity. In human and animal models of ARDS, inhaled lipid emulsions of omega-3 fatty acids attenuate pro-inflammatory cytokine production and immune cell response. Meanwhile, a meta-analysis examining enteral omega-3 fatty acids for treating ARDS was inconclusive.

Patients with COVID-19 infection are vulnerable to the development of ARDS, and omega-3 fatty acids may serve as a useful preventive and therapeutic agent for ARDS in COVID-19. Investigation into the role of omega-3 fatty acids in COVID-19 is ongoing, with 10 currently registered trials in clinicaltrials.gov. Concerns about fish oils contributing to arrhythmia and bleeding risk are debated. Omega-3 fatty acid oral supplementation can cause mild gastrointestinal discomfort, and therefore should generally be taken with meals. Oxidation of omega-3 fatty acids is pro-inflammatory, and therefore combining omega-3 fatty acid with other antioxidants may reduce oxidative damage to the supplement.

**Micronutrient and Antioxidant Support**

While micronutrients have pluripotent effects, those micronutrients that have been studied in relation to COVID-19 have primarily antioxidant and anti-inflammatory effects (Tables 3 and 4). Emerging research on COVID-19 has examined the inflammatory cascade and endothelial dysfunction as a major contributor to clinical pathology, and insufficiency or deficiency of selected micronutrients has been associated with higher likelihood of infection and/or complications related to COVID-19. We discuss several of the most commonly utilized micronutrient and antioxidant strategies below.

**Intravenous High-Dose Ascorbic Acid (Vitamin C)**

Vitamin C is an essential antioxidant and enzyme cofactor to several vital biochemical pathways. When given intravenously in high doses (50 mg/kg up to 100 grams or higher, daily), vitamin C may improve clinical outcomes in patients with sepsis and several cancers, though research is ongoing. Poor outcomes in sepsis are associated with significantly reduced plasma vitamin C concentrations. In sepsis, there is increased consumption of vitamin C by somatic cells combined with high leukocyte turnover, triggered by an overwhelming state of oxidative stress that then contributes to higher levels of reactive oxygen species (ROS). At high serum concentrations, only attainable by intravenous administration (millimolar [mM] range), vitamin C seems to elicit a dual response with both antioxidant and pro-oxidant properties depending on cell type.

Activated immune cells with high turnover rates rely on accelerated glycolysis (the “Warburg effect”) while others such as lung epithelial cells rely on oxidative phosphorylation for energy production. High doses of vitamin C can overwhelm the redox pathways in highly glycolytic cells leading to elevated endogenous ROS. Increased oxidative stress, together with inhibition of ATP production from high levels of ROS, leads to a cellular energy crisis and cell death. This may provide a mechanism of immunosuppression by preventing myeloid and lymphoid cells’ hyperactivation, yet still providing antioxidant protection to lung epithelial cells.

Prior trials utilizing high-dose vitamin C for conditions such as sepsis demonstrate mixed results. More recent studies show a potential mortality benefit with high-dose vitamin C given intravenously combined with steroids for patients with sepsis complicated by acute respiratory distress syndrome (ARDS). These findings and many others related to vitamin C have led to numerous clinical trials evaluating this strategy’s effectiveness in critically-ill patients with COVID-19. In addition, vitamin C is being examined in conjunction with other supplements to regulate oxidative effects at lower doses, such as with quercetin. At the time of this publication, there are currently 32 registered clinical trials utilizing vitamin C in various dosing strategies (including oral supplementation) and in combination with other therapies.
Table 3. Micronutrients and COVID-19.

| Supplement       | Mechanism of action and potential benefits                                                                 | Potential harms or adverse reactions                                                                 | Association with COVID-19 infection                                                                 | Ongoing registered clinical trials related to COVID-19 |
|------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Ascorbic acid    | • Antioxidant and enzyme cofactor<br>• May limit pro-oxidant effects when given in conjunction with other supplements<br>• Pro-oxidant properties at higher doses when given IV which may inhibit hyperactivation of over-stimulated myeloid and lymphoid cells | • Oral: abdominal pain, diarrhea<br>• IV (high-dose): hemolytic anemia in patients with G6PD-deficiency; glucose | • Vitamin C levels are depleted during the acute stage of infection due to increased metabolic demands<br>• Many patients with severe COVID-19 have elevated levels of the mediators interleukin-6 and endothelin-1 which may explain the propensity of COVID19 pneumonia for elderly, male, obese, hypertensive patients, as well as of persons of color and smokers. Vitamin C in high doses can reduce these mediators | • There are 53 registered clinical trials related to Vitamin C and COVID19 on clinicaltrials.gov |
| Cholecalciferol  | • Supports both innate and adaptive immune mechanisms<br>• Inhibition of T cell proliferation, production of cytokines, antibody synthesis by B lymphocytes<br>• Stimulate surfactant synthesis in alveolar cells | • Hypercalcemia which can lead to gastric distress, muscle weakness, neuropsychiatric disturbances, dehydration, polyuria, nephrolithiasis, and fatal cardiac arrhythmias | • Vitamin D deficiency has been correlated with poor outcomes in COVID-19<br>• Vitamin D supplementation along with magnesium and Vitamin B12 mitigated clinical deterioration in elderly patients with COVID-19 infection | • There are 73 registered clinical trials related to vitamin D supplementation and COVID19 on clinicaltrials.gov |
| Zinc             | • Preserves natural tissue barriers such as the respiratory epithelium, improves mucociliary clearance, decreases viral replication, attenuates inflammation, and minimizes secondary respiratory infections | • If large doses of zinc (10-15 times higher than the RDA) are taken by mouth even for a short time, stomach cramps, nausea, and vomiting may occur. Ingesting high levels of zinc for several months may cause anemia, damage the pancreas, and decrease levels of high-density lipoprotein (HDL) cholesterol. | • COVID-19 infection and survival associated with zinc deficiency<br>• Both zinc deficiency and early COVID-19 infection are uniquely associated with loss of taste<br>• Zinc supplementation reduced time to recovery of smell and/or taste<br>• Zinc deficiency is common in patients at risk for COVID-19; screening for zinc deficiency may be helpful are at the same time groups that are associated with zinc deficiency | • There are 46 registered clinical trials related to zinc supplementation and COVID19 on clinicaltrials.gov |

(continued)
as a treatment strategy for various stages of COVID-19 severity. Due to inhibition of glycolytic pathways, individuals must be tested for glucose-6-phosphate dehydrogenase deficiency before receiving high-dose vitamin C, as this can lead to hemolytic anemia from increased oxidative stress in enzyme-deficient erythrocytes. Otherwise, excess vitamin C is cleared renally and is generally well tolerated.

Cholecalciferol (Vitamin D3)

Emerging research indicates vitamin D may have an essential role in the function and regulation of innate and adaptive immunity. Vitamin D deficiency contributes to increases in seasonal respiratory viral infections, and disproportionately impacts those likely to be deficient, including individuals who are older, obese, smokers, have dark skin tone, live in more northern latitudes and in individuals with genetic variants impeding vitamin D status. This particularly alarming for African-Americans, who experience high rates of vitamin D deficiency and suffer a 3-fold higher rate of COVID-19 infection and a 6-fold higher death rate due to COVID-19 as compared to Caucasians. Thus, vitamin D status may significantly impact vulnerability to infection from COVID-19.

There are roughly 2 dozen RCTs and 10 observational studies exploring vitamin D supplementation as an adjunct treatment for COVID-19 infection. Cross-sectional observational studies have shown that vitamin D deficiency is associated with risk of COVID-19 infection and worse disease severity. In 1 observational study, supplementation with cholecalciferol combined with magnesium and B12 showed less clinical deterioration and reduced the need for intensive care in elderly patients with COVID-19. Researchers are using both high- and standard-dose vitamin D combined with various other agents, including hydroxychloroquine, azithromycin, vitamin C, zinc, and aspirin as a potential treatment.

Vitamin D supplementation has minimal side effects, however vitamin D toxicity is associated with kidney stones and hypercalcemia and should be avoided.

Zinc

Zinc has multiple effects on protecting the respiratory system from viral infection, including preserving respiratory epithelial linings, improving mucociliary clearance, decreasing viral replication, attenuating local inflammation, and minimizing secondary respiratory infections. Zinc deficiency is underrecognized and undertreated, and affects up to one-third of the world population. The WHO asserts that roughly 1 in 6 deep respiratory infections worldwide can be attributed to zinc deficiency, with a preponderance toward children in developing countries.

Early data suggests a role of zinc in the manifestation of COVID-19 symptoms. Both zinc deficiency and early

Table 3. (continued)

| Supplement                      | Mechanism of action and potential benefits                                                                 | Potential harms or adverse reactions          | Association with COVID-19 infection                                      | Ongoing registered clinical trials related to COVID-19 |
|--------------------------------|-------------------------------------------------------------------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------|
| Nicotinamide riboside (Vitamin B3) | • Restoration and balance of cellular energy function and stabilization of oxidation/reduction pathways         | • No significant adverse effects reported. Mild gastrointestinal symptoms | • SARS-CoV-2 must exploit host functions, including nucleic acid and protein synthesis, to assemble more viruses. Both viruses and hosts rely on nicotinamide adenine dinucleotide derivatives, as these coenzymes accept and donate electrons in numerous essential biological processes | • There are 2 registered clinical trials related to nicotinamide riboside supplementation and COVID-19 on clinicaltrials.gov |
Table 4. Antioxidants and COVID-19.

| Supplement | Mechanism of action and potential benefits | Potential harms or adverse reactions | Association with COVID-19 infection | Ongoing registered clinical trials related to COVID-19 |
|------------|-------------------------------------------|-------------------------------------|-----------------------------------|----------------------------------------------------|
| Glutathione | • Antioxidant involved in metabolic regulation and promoting cellular homeostasis | • Gastric cramping, nausea, abdominal bloating, and allergic reactions have been reported.  
• Chronic supplementation linked to low serum zinc concentrations.  
• Inhaled glutathione reported to trigger asthma attacks.  
• FDA has warned that glutathione powders used to prepare injectable forms may contain endotoxins that can cause myalgia, arthralgia, nausea, vomiting, and hypotension. | • May help to mitigate ARDS response to COVID-19 infection | • There are 5 registered clinical trials related to glutathione supplementation and COVID-19 on clinicaltrials.gov |
| N-acetylcysteine | • Antioxidant in the extracellular environment to increase intracellular penetration of glutathione  
• Increases pulmonary defense mechanisms through its natural antioxidant properties and its indirect role in glutathione synthesis  
• Has been shown to thin mucus buildup in the lungs of elderly individuals with influenza  
• Has been shown to reduce levels of toxic hydrogen peroxide concentration in exhaled air condensate, | • As noted above for glutathione | • May help to mitigate ARDS response to COVID-19 infection | • There are 14 registered clinical trials related to glutathione supplementation and COVID-19 on clinicaltrials.gov |
| Quercetin | • Anti-carcinogenic, anti-inflammatory, antiviral, antioxidant, and psychostimulant activities  
• Ability to inhibit lipid peroxidation, platelet aggregation and capillary permeability, and to stimulate mitochondrial biogenesis | • Prior studies demonstrated that quercetin unexpectedly depleted intracellular glutathione, causing pro-oxidant effects.  
• Potentially harmful interactions with statins, cyclosporine, and fexofenadine have been reported | • May alter the expression of human genes encoding protein targets of SARS-CoV-2 | • There are 4 registered clinical trials related to quercetin supplementation and COVID-19 on clinicaltrials.gov |

(continued)
Table 4. (continued)

| Supplement | Mechanism of action and potential benefits | Potential harms or adverse reactions | Association with COVID-19 infection | Ongoing registered clinical trials related to COVID-19 |
|------------|------------------------------------------|------------------------------------|----------------------------------|---------------------------------------------------|
| Curcumin   | • Anti-inflammatory, antioxidant<br>• Potentially binds to both the ACE2 receptor and receptor-binding domain of the SARS-CoV-2 spike protein (blocking viral entry) | • Cardiotoxicity from binding hERG channels | • May inhibit COVID-19 binding of spike protein, thereby reducing viral infectivity | • There is 1 registered clinical trial related to curcumin and COVID-19 on clinicaltrials.gov |
| Melatonin  | • Anti-inflammatory, antioxidant<br>• Inhibition of the NLRP3 inflammasome<br>• May reduce vessel permeability, alleviate anxiety, and improve sleep quality | • Alters sleep cycles, which may contribute to poor sleeping patterns and insomnia<br>• May cause headache, confusion, dizziness, somnolence, and nausea | • COVID-19 may attack the melatonin synthetic pathway<br>• Melatonin may reduce vessel permeability, alleviate anxiety, and improve sleep quality in COVID-19 patients | • There are 8 registered clinical trials related to melatonin and COVID-19 on clinicaltrials.gov |
| Cannabidiol (CBD) | • Interferes with ACE2-mediated viral entry into cells<br>• Anti-inflammatory | • Risk of anxiety, psychosis, and euphoria in products containing THC<br>• Lung damage and inflammation from smoking or vaping marijuana products | • Downregulation of inflammatory cytokines including TNFa and IL-6, major contributors to progression to ARDS in COVID-19 | • There are 8 registered clinical trials related to cannabinoids and COVID-19 on clinicaltrials.gov |

COVID-19 infection are uniquely associated with loss of smell and taste, and zinc supplementation may reduce time to recovery of smell and/or taste. Additionally, both conditions overlap in terms of demographic and risk factor profiles. This suggests a common pathway to smell and taste alteration for which zinc may prove useful as a therapeutic agent. Zinc serum levels may also predict survival when combined with selenium levels, and further investigation of the mechanism of this relationship is needed. There are currently 46 registered clinical trials related to zinc supplementation and COVID-19 on clinicaltrials.gov. Registered clinical trials are investigating zinc largely in combination with vitamins C and D to reduce disease severity and lessen duration of COVID-19 infection. Zinc is also being investigated as an adjunct treatment to hydroxychloroquine in addition to other nutraceuticals. Zinc supplementation is fairly harmless, but zinc toxicity on the order of >10 times the recommended daily allowance can result in gastrointestinal upset and over time result in anemia, pancreatic injury, and reductions in high-density lipoprotein cholesterol.

**Nicotinamide Adenine Dinucleotide and Its Precursors, Nicotinamide Riboside**

Nicotinamide adenine dinucleotide (NAD) serves essential biochemical functions in metabolic pathways and also contributes heavily to cellular immunity. NAD assists in the function of interferon-inducible proteins such as ADP-ribosyltransferases (PARPs), which perform a wide range of cellular and immune functions. Some of these functions include suppression of cellular protein synthesis and cellular metabolism, all of which result in suppression of viral replication in infected cells. This mechanism allows for the innate immune response to counter viral infections and preserve cellular function and health. Additionally, NAD has been associated with better glycemic control and neuroprotective effects via its involvement in catabolic pathways, and has demonstrated cardioprotective effects via lipid metabolism and relief of oxidative stress.

Early studies of the COVID-19 virus have revealed similar actions to other viruses in the suppression of innate immunity and the development of metabolic derangements that contribute to comorbidity of disease. A conserved ADP-ribosehydrolase domain on the COVID-19 virus induces overexpression of PARPs, contributing to consumption of NAD and impaired resistance to the hijacking of cellular machinery for viral replication. Indeed, COVID-19 infection in vitro was seen to suppress synthesis of NAD from amino acids, causing cells to derive their NAD production from other forms of NAD, including nicotinamide and nicotinamide riboside. These other forms of NAD enzymatically support the production of NAD, and therefore depletion of these forms can further diminish the cell’s capacity to maintain physiologic...
levels of NAD. Supplementation with NAD can therefore be achieved with supplementation with nicotinamide riboside, which will enhance NAD production in the body. There are currently 2 ongoing clinical trials investigating whether 1 gram of nicotinamide riboside given orally for 14 days can reduce COVID-19 infection severity in elderly patients. The supplement is very well tolerated, and it should be noted that flushing is not seen with ingestion of nicotinamide, unlike niacin for which this side effect is well documented and often difficult to tolerate.

**Glutathione, N-Acetylcysteine, and Synthetic Organoselenium (Ebselen)**

Glutathione (GSH), and its precursor N-acetylcysteine (NAC), are potent antioxidants which may be vital in host defense against COVID-19. Clinical trials are exploring antioxidant therapy in COVID-19 with GSH, NAC, and Ebselen, a synthetic organoselenium that biologically mimics glutathione peroxidase. GSH is an essential and complex detoxification agent involved in metabolic regulation and promotes cellular homeostasis. Although GSH poorly penetrates cells, its precursor, NAC, works as an antioxidant in the extracellular environment to increase intracellular penetration of GSH. While NAC by itself has antioxidant properties to protect respiratory epithelium from injury, NAC indirectly increases availability of GSH intracellularly for cellular health. In small clinical trials, NAC reduces hydrogen peroxide in exhaled air of patients with COPD, demonstrating the antioxidant effects of NAC supplementation.

Multiple mechanisms have been proposed in support of antioxidant therapy for COVID-19. With a broad range of antioxidant and anti-inflammatory mechanisms, NAC may increase glutathione and further attenuate the risk of severe complications from COVID-19, as previously demonstrated for influenza and other respiratory illnesses. There are 5 registered clinical trials related to glutathione supplementation and COVID-19 and 14 registered clinical trials related to NAC supplementation and COVID-19 on clinicaltrials.gov. A phase 3 randomized placebo-controlled trial is currently underway to assess NAC’s efficacy in preventing COVID-19 progression in severity. Moreover, high-dose intravenous NAC is also being studied in clinical trials as an adjuvant in treating severe cases of COVID-19.

Risks associated with glutathione supplementation including gastric cramping, nausea, abdominal bloating, and allergic reactions have been reported. Chronic supplementation has been linked to low serum zinc concentrations, and inhaled glutathione has been reported to trigger asthma attacks. The FDA has warned that glutathione powders used to prepare injectable forms may contain endotoxins that can cause myalgia, arthralgia, nausea, vomiting, and hypotension. Therefore, inhaled forms of glutathione should be avoided.

**Polyphenolic Compounds**

**Quercetin**

Abundant in foods such as onions, juniper berries and many other fruits and vegetables, quercetin is a type of flavonoid, a class of antioxidant compounds that has been studied extensively for anti-inflammatory and antiviral actions, among other potential benefits. Quercetin inhibits lipid peroxidation via antioxidant actions, and supports mitochondrial health via its role in the protecting against ROS production. Quercetin can also demonstrate pro-oxidant effects. In a prior study unrelated to COVID-19, quercetin unexpectedly depleted intracellular glutathione, a vital antioxidant involved in ROS scavenging system. It is reasonable to consider that this seemingly pro-oxidant effect may be similar to that of high dose vitamin C by helping to suppress overstimulated immune effector cells during viral infection, thereby mediating the inflammatory response.

These findings show that quercetin may demonstrate complex mediation of oxidation to quell viral infections such as COVID-19. Quercetin effectively inhibits the hyperinflammatory response triggered by COVID-19 infection through the inflammasome pathway, which results in an exaggerated release of proinflammatory cytokines, IL-6 and IL-1. Quercetin may have epigenetic effects as well, altering the expression of COVID-19 viral proteins in human cells. It has been proposed that combining quercetin with vitamin C takes advantage of quercetin’s effect on COVID-19 viral protein function while limiting degree of pro-oxidant effects to prevent toxicity. Current open-label trials are evaluating quercetin both for prophylaxis and treatment of COVID-19, which will help identify the most effective and safe regimen. There are 4 registered clinical trials related to quercetin supplementation and COVID-19 on clinicaltrials.gov. Flavanoid supplementation is generally well tolerated, and quercetin is no exception.

**Curcumin**

Traditionally used in Asian countries as a medical herb, curcumin (diferuloylmethane) has reported antioxidant, anti-inflammatory, antimicrobial and anti-cancer properties. Curcumin has previously demonstrated several anti-inflammatory as well as antiviral properties through inhibition of various proinflammatory cytokines. Potentially binding to both the ACE2 receptor in addition to the receptor-binding domain of the SARS-CoV-2 protein, some studies suggest curcumin may act as an inhibitory agent by blocking viral host interaction at entry sites in human cells. Notably, curcumin accelerated endothelial cell restoration and endothelium recovery, which may be beneficial in tempering the overwhelming endothelial damage associated with severe cases of COVID-19.

Despite several potential benefits and overall favorable safety profile of curcumin, poor oral absorption in conjunction with rapid metabolism of curcumin result in overall low bioavailability. However, heat extraction techniques and curcumin
nanocarriers have improved bioavailability with increased cellular uptake in some studies. 105 Although serious side effects are rare, curcumin has reported activity against several human enzymes linked to compound toxicity, including hERG channels (leading to cardiotoxicity). 106 The NCCIH warns that no conclusions have been reached on curcumin’s ability to provide any benefit for human medical conditions. 107 There is 1 registered clinical trial related to curcumin and COVID-19 on clinicaltrials.gov. Researchers are currently investigating a combination of curcumin, artemisinin, frankincense, and vitamin C as a possible strategy to promote clinical improvement in patients with COVID-19.

**Melatonin**

Melatonin, an antioxidant and anti-inflammatory agent, has demonstrated clinical benefit in sepsis and many viral infections. 108 Researchers are exploring its use for COVID-19 by focusing on melatonin’s capacity to reduce vessel permeability, alleviate anxiety, and increase sleeping quality to improve clinical outcomes. 109-111 As a modulator of the cytokine storm, melatonin can ameliorate activation of the nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing receptor 3 (NLRP3) inflammasome. 111 This intracellular component secretes proinflammatory chemicals in response to infection. 112 Adverse reactions include, altered sleep cycles, which may contribute to poor sleeping patterns and insomnia and potential headache, confusion, dizziness, somnolence, and nausea.

There are currently 8 registered RCTs evaluating melatonin (or its agonist, ramelteon) to reduce symptom severity or prevent COVID-19. 112 A current clinical trial is evaluating the therapeutic effects of melatonin via inhibition of the NLRP3 inflammasome in patients hospitalized with COVID-19 infection. 112 Some hypotheses have suggested that COVID-19 may attack the melatonin synthetic pathway, thereby reducing melatonin levels, and the presence of the virus in neural tissue may explain the reduced physiological levels of melatonin. 113 Moreover, investigation of melatonin supplementation in exposed healthcare workers to prevent infection with SARS-CoV2 is ongoing. 114

**Cannabinoids**

Utilization of cannabis terpenes and cannabis-derived cannabidiol (CBD) as adjunct anti-inflammatory treatments for COVID-19 infection is under investigation. 115 Cannabinoids, specifically, the non-psychotropic portion cannabidiol (CBD), has previously demonstrated efficacious reduction of inflammation in preclinical models of numerous diseases. 116 Recently, researchers discovered at least 13 high-potency CBD cannabis strains which can affect ACE2 pathways, concluding that hemp extracts rich in CBD may interfere with the ability of SARS-CoV-2 to enter host cells. 117

CBD inhibits the production of several proinflammatory cytokines primarily through inhibition of toll like receptor-4 (TLR4) activity, which is corroborated in humans who consume cannabis. 118 Tissue models have previously demonstrated marked inhibition of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) using various Sativa strains of cannabis that also contain high amounts of CBD. 119 Given the vast distribution of the endocannabinoid system in the human body, 118 it is plausible that CBD may be beneficial in treating inflammatory conditions, including those associated with COVID-19.

Current trials are investigating high-concentration CBD tablets in conjunction with steroids or antiviral medications for COVID-19. 120 There are 8 registered clinical trials associated with cannabinoids and COVID-19 on www.clinicaltrials.gov. In particular, 1 RCT is evaluating a 14 course of CBD in reducing viral load and inflammatory cytokines while improving the quality of life in patients with COVID-19. 121 Additionally, CBD has been shown to reduce depression, anxiety, and stress—potentially enhancing the human body’s innate ability to fight infection by lessening the deleterious effects of psychological stress on immune function. There is a single-arm study evaluating CBD for burnout prevention in frontline healthcare workers dealing with SARS-CoV-2 exposure. 122 Despite the promising potential of CBD, products that contain THC may lead to anxiety, psychosis, and euphoria. 123 Moreover, smoking or vaping should be strongly discouraged to patients. This may damage lung endothelial cells and the ciliary network, potentially increasing susceptibility to respiratory pathogens. 124

**Special Mention of Supplements Which Should be Considered With Caution**

The COVID-19 pandemic has generated a spike in interest regarding natural therapies for this disease, driving up sales of certain supplements by over 400% (Table 5). 125 Unfortunately, some disingenuous business have seized on the opportunity to advertise COVID-19 treatments with minimal peer-reviewed evidence for benefit, and for some, significant potential harms. Nevertheless, these supplements have gained attention in the public domain, mostly from non-peer-reviewed sources including online health forums, political leaders, and news outlets. Thus far, the FDA has sent over 40 warning letters to companies and a preliminary injunction to a company refusing to remove from the market its “Miracle Mineral Solution” found to be a chlorine dioxide product, equivalent to industrial bleach. 126 Additional products are described below as well as in Table 5.

**Elderberry (Sambucus)** may potentiate the COVID-19 cytokine storm by increasing levels of IL-6 and TNF-a; while it is generally considered low risk, some integrative health experts advise discontinuation of elderberry for above stated reason if one contracts COVID-19. 127 Currently, there are no registered clinical trials exploring elderberry as a therapeutic or preventive agent in coronavirus. Most recommendations for its use come from anecdotal evidence gleaned from studies with viral infections such as influenza. 128-130 We urge caution
before recommending this to patients until elderberry is studied specifically in the context of COVID-19 infection.

**Colloidal silver** can cause significant adverse effects if used inappropriately or at high doses including peripheral neuropathy and argyria—a bluish-gray, potentially permanent discoloration of the skin.\(^{131}\) The National Center for Complementary and Integrative Health (NCCIH) affirms that colloidal silver has “no known function or benefits when taken by mouth.” To our knowledge, there are no registered trials exploring the use of colloidal silver for the treatment of COVID-19. Unfortunately, a variety of supplement companies have advertised purported benefits of colloidal silver for treatment of COVID-19, prompting FDA warning letters.\(^{132}\) Given the potential harms and lack of evidence for benefit, practitioners are discouraged from using this supplement until further evidence is available.

**Licorice** (Glycyrrhiza glabra) is undergoing a feasibility trial\(^ {136}\) for COVID-19, however, due to potential cardiac toxicity,\(^ {137}\) practitioners should inform patients of the potential dangers associated with this natural cardiac glycoside and recommend against its use until well-validated clinical trials evaluate safety and efficacy for COVID-19.\(^ {138}\)

**Authors’ Note**
Melody Hermel and Megan Sweeney are co-first authors. The study is from the Scripps Clinic and Scripps Center for Integrative Medicine.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received no financial support for the research, authorship, and/or publication of this article.

---

**Table 5. Potential Harmful Substances Related to COVID-19.**

| Supplement           | Mechanism of action and potential benefits | Potential harms or adverse reactions | Ongoing registered clinical trials related to COVID-19 |
|----------------------|-------------------------------------------|-------------------------------------|-----------------------------------------------------|
| Elderberry (Sambucus) | • Antiviral activity, especially in context of influenza pneumonia | • May increase TNFa and IL-6 levels, exacerbating cytokine storm contributing to ARDS in COVID-19 | • There are zero registered clinical trials related to elderberry and COVID-19 on clinicaltrials.gov |
| Colloidal silver     | • Antibacterial and potentially antiviral properties when administered topically | • May cause peripheral neuropathy or argyria with oral high doses | • There is 1 registered clinical trial related to colloidal silver and COVID-19 on clinicaltrials.gov |
| Licorice (Glycyrrhiza glabra) | • Herbal medicine with purported benefits for cough or febrile illness | • May cause pseudoaldosteronism with hypertension and possibly death | • There are 2 registered clinical trials related to licorice and COVID19 on clinicaltrials.gov |
| Oleander (Nerium oleander) | • Herbal medicine with unclear medicinal value | • Cardiac glycoside action may cause arrhythmias and possibly sudden cardiac death | • There is 1 registered clinical trial related to oleander and COVID19 on clinicaltrials.gov |

---

**Conclusion**
Grappling to calm the ubiquitous turmoil of a worldwide pandemic, investigators have been galvanized into an expedient growth of research and ongoing clinical trials searching for effective strategies to prevent and treat COVID-19. Considering limited treatment options for COVID-19, patients and clinicians alike are increasingly turning to natural supplements in the hopes of finding effective therapeutics and adjuncts to regular care to promote immune function, diminish infectivity, and reduce the severity and duration of illness. Here the authors present a mélange of the scientific evidence and rationale for ongoing trials utilizing natural supplements in the setting of COVID-19. Natural supplements including micronutrients (vitamin C, vitamin D; zinc, NAD), probiotics, antioxidants (GSH and NAC), as well as melatonin and cannabis are being clinically investigated as an adjunct in therapy for COVID-19. Several natural supplements popular with patients, however, are not being investigated in rigorous clinical trials or are inherent with potential harms. Awaiting the results from such trials, the authors’ objective is to arm clinicians with the necessary knowledge and background scientific evidence to appropriately guide patients in their selection of alternative and complementary supplements for COVID-19 prophylaxis and treatment undergoing current clinical trials.
References

1. Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ. 2020;370:m2924. doi:10.1136/bmj.m2924
2. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. doi:10.15585/mmwr.mm695152e2
3. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:10.15585/mmwr.mm695152e1
4. Dickinson A, Blatman J, El-Dash N, Franco JC. Consumer usage and reasons for using dietary supplements: report of a series of surveys. J Am Coll Nutr. 2014;33(2):176-182. doi:10.1080/073153724.2013.875423
5. Dietary Supplement Use Reaches All Time High. The Council for Responsible Nutrition (CRN). 2019. Accessed June 1, 2020. https://www.crnusa.org/newsroom/dietary-supplement-use-reaches-all-time-high
6. Foley H, Steel A, Cramer H, Wardle J, Adams J. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Sci Rep. 2019;9(1):1573. doi:10.1038/s41598-018-38279-8
7. Crawford C, Boyd C, Avula B, Wang YH, Khan IA, Deuster PA. A public health issue: dietary supplements promoted for brain health and cognitive performance. J Altern Complement Med N Y N. 2020;26(4):265-272. doi:10.1089/acm.2019.0447
8. Natural medicines. Therapeutic research center. 2021. Accessed March 1, 2021. https://naturalmedicines.therapeuticresearch.com/
9. Herbal Medicines Compendium. The United States pharmacopeial convention. 2021. Accessed March 2, 2021. https://hmc.usp.org/
10. ConsumerLab.com. 2021. Accessed March 3, 2021. https://www.consumerlab.com/
11. Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun. 2020;87:53-54. doi:10.1016/j.bbi.2020.04.040
12. Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015;8(5):5153-5160.
13. Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Front Immunol. 2017;8:598. doi:10.3389/fimmu.2017.00598
14. Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and dysbiosis therapy in critical illness. Curr Opin Crit Care. 2016;22(4):347-353. doi:10.1097/MCC.0000000000000321
15. Valdés-Varela L, Gueimonde M, Ruas-Madiedo P. Probiotics for prevention and treatment of clostridium difficile infection. Adv Exp Med Biol. 2018;1050:161-176. doi:10.1007/978-3-319-72799-8_10
16. Chong HX, Yusoff NAA, Hor YY, et al. Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: a randomized, double-blind, placebo-controlled study. J Dairy Sci. 2019;102(6):4783-4797. doi:10.3168/jds.2018-16103
17. Kanauchi O, Andoh A, AbuBakar S, Yamamoto N. Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. Curr Pharm Des. 2018;24(6):710-717. doi:10.2174/1381612824666180116163411
18. King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr. 2014;112(1):41-54. doi:10.1017/S0007114514000075
19. Zeng J, Wang CT, Zhang FS, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016;42(6):1018-1028. doi:10.1007/s00134-016-4303-x
20. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058-1064. doi:10.1164/rccm.200912-1853OC
21. Ceccarelli G, Scagnolari C, Pugliese F, Mastroianni CM, d’Ettorre G. Probiotics and COVID-19. Lancet Gastroenterol Hepatol. 2020;5(8):721-722. doi:10.1016/S2468-1253(20)30196-5
22. Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69(8):1543-1544. doi:10.1136/gutjnrl-2020-321388
23. Verdeccchia P, Cavallini C, Spanevolo A, Angelii F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14-20. doi:10.1016/j.ejim.2020.04.037
24. Perlot T, Penninger JM. ACE2—from the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect. 2013;15(13):866-873. doi:10.1016/j.micinf.2013.08.003
25. Xu K, Cai H, Shen Y. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhongguo Jiu Yu Xin Bi Xue Bao Yi Xue Ban J Zhejiang Univ Med Sci. 2020;49(1):147-157. doi:10.3785/j.issn.1008-9292.2020.02.02
26. Biosearch SA. Multicentric Study to Assess the Effect of Consumption of Lactobacillus Corynformis K8 on Healthcare Personnel Exposed to COVID-19. Clinicaltrials.gov; Published 2020. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04366180
27. Posaica R. Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients with COVID-19 Associated with Modulation of the Gut Microbial Flora. Clinicaltrials.gov; Published 2020. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04366089
28. Kwok LY, Zhang J, Guo Z, et al. Characterization of fecal microbiota across seven Chinese ethnic groups by quantitative polymerase chain reaction. PLoS One. 2014;9(6):e93631. doi:10.1371/journal.pone.0093631
29. Gueimonde M, Collado MC. Metagenomics and probiotics. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18(suppl 4):32-34. doi:10.1111/j.1469-0691.2012.03873.x
30. Ibrahim MK, Zambruni M, Melby CL, Melby PC. Impact of childhood malnutrition on host defense and infection. Clin Microbiol Rev. 2017;30(4):919-971. doi:10.1128/CMR.00119-16
31. Lew CCH, Yandell R, Fraser RJL, Chua AP, Chong MFF, Miller M. Association between malnutrition and clinical outcomes in the intensive care unit: a systematic review [formula: see text]. JPEN J Parenter Enteral Nutr. 2017;41(5):744-758. doi:10.1177/0148607115625638
32. Paynter S, Ware RS, Lucero MG, et al. Malnutrition: a risk factor for severe respiratory syncytial virus infection and hospitalization. Pediatr Infect Dis J. 2014;33(3):267-271. doi:10.1097/ INF.0000000000000996
33. Rodríguez L, Cervantes E, Ortiz R. Malnutrition and gastrointestinal and respiratory infections in children: a public health problem. Int J Environ Res Public Health. 2011;8(4):1174-1205. doi:10.3390/ijerph8041174
34. Hruby A, Jacques PF. Dietary protein and changes in biomarkers of inflammation during COVID-19 lockdown: an Italian survey. J Transl Med. 2020;18:18. doi:10.1186/s12967-020-02399-5
35. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005;81(2):341-354. doi:10.1093/ajcn.81.2.341
36. Li T, Zhang Y, Gong C, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr. 2020;74(6):871-875. doi:10.1038/s41430-020-0642-3
37. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005;81(2):341-354. doi:10.1093/ajcn.81.2.341
38. Di Renzo L, Gualtieri P, Pivari F, et al. Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. J Transl Med. 2020;18(1):229. doi:10.1186/s12967-020-02399-5
39. Angelidi AM, Kokkinos A, Katechaki E, Ros E, Mantzoros CS. Mediterranean diet as a nutritional approach for COVID-19. Metabolism. 2021;114:154407. doi:10.1016/j.metabol.2020.154407
40. Singh P, Tripathi MK, Yasir M, Khare R, Tripathi MK, Shrivastava R. Potential inhibitors for SARS-CoV-2 and functional food components as nutritional supplement for COVID-19: a review. Plant Foods Hum Nutr. 2020;75(4):458-466. doi:10.1007/s11130-020-00861-9
41. Fragopoulou E, Panagiotakos DB, Pitsavos C, et al. The association between adherence to the Mediterranean diet and adiponectin levels among healthy adults: the ATTICA study. J Nutr Biochem. 2010;21(4):285-289. doi:10.1016/j.jnutbio.2008.12.013
42. Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? Arch Med Res. 2020;51(3):282-286. doi:10.1016/j.arcmed.2020.03.004
43. Kang KW, Kim S, Cho YB, Ryu SR, Seo YJ, Lee SM. Endogenous n-3 polyunsaturated fatty acids are beneficial to dampen CD8+ T cell-mediated inflammatory response upon the viral infection in mice. Int J Mol Sci. 2019;20(18). doi:10.3390/ijms20184510
44. Eslamloo K, Xue X, Hall JR, et al. Transcriptome profiling of antiviral immune and dietary fatty acid dependent responses of Atlantic salmon macrophage-like cells. BMC Genomics. 2017;18(1):706. doi:10.1186/s12864-017-4099-2
45. Hecker M, Linder T, Ott J, et al. Immunomodulation by lipid emulsions in pulmonary inflammation: a randomized controlled trial. Crit Care Lond Engl. 2015;19(1):226. doi:10.1186/s13054-015-0933-6
46. Dushianthan A, Cusack R, Burgess VA, Grocott MP, Calder PC. Immunonutrition for Acute Respiratory Distress Syndrome (ARDS) in adults. Cochrane Database Syst Rev. 2019;1:CD012041. doi:10.1002/14651858.CD012041.pub2
47. Rogero MM, Leão M de C, Santana TM, et al. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. Free Radic Biol Med. 2020;156:199-200. doi:10.1016/j.freeradbiomed.2020.07.005
48. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD003177. doi:10.1002/14651858.CD003177.pub3
49. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038-3044. doi:10.1093/eurheartj/ehaa623
50. Froldi G, Dorigo P. Endothelial dysfunction in coronavirus disease 2019 (COVID-19): gender and age influences. Med Hypotheses. 2020;144:110015. doi:10.1016/j.mehy.2020.110015
51. Ngo B, Van Riper JM, Cantley LC, Yun J. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019;19(5):271-282. doi:10.1038/s41568-019-0135-7
52. Marik PE. Hydrocortisone, ascorbic acid and thiamine (HAT Therapy) for the treatment of sepsis. Focus on ascorbic acid. Nutrients. 2018;10(11). doi:10.3390/nu10111762
53. Erol A. High-dose intravenous vitamin C treatment for COVID-19. 2020. doi:10.31219/osf.io/p7ex8
54. Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575-580. doi:10.1038/s41586-019-1678-1
55. Fujii T, Luethi N, Young PJ, et al. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA. 2020;323(5):423-431. doi:10.1001/jama.2019.22176
56. Hager DN, Hooper MH, Bernard GR, et al. The vitamin C, thiamine, and steroids in sepsis (VICTAS) protocol: a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials. 2019;20(1):197. doi:10.1186/s13063-019-3254-2
57. Fowler AA, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261-1270. doi:10.1001/jama.2019.11825
58. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of
severe sepsis and septic shock: a retrospective before-after study. *Chest*. 2017;151(6):1229-1238. doi:10.1016/j.chest.2016.11.036

59. Feyaerts AF, Luyten W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? *Nutr Burbank Los Angel Cty Calif*. 2020;79-80:110948. doi:10.1016/j.nut.2020.110948

60. Abobaker A, Alzwi A, Alraiedi AHA. Overview of the possible role of vitamin C in management of COVID-19. *Pharmacol Rep*. 2020;72(6):1517-1528. doi:10.1007/s43440-020-00176-1

61. Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). *Front Immunol*. 2020;11:1451. doi:10.3389/fimmu.2020.01451

62. Tehran University of Medical Sciences. Preventive and Therapeutic Effects of Oral 25-Hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04386850

63. Kohlmeier M. Avoidance of vitamin D deficiency to slow the COVID-19 pandemic. *BMJ Nutr Prev Health*. 2020;3(1):67-73. doi:10.1136/bmjnph-2020-00096

64. Jain SK, Parsanathan R. Can vitamin D and L-cysteine co-supplementation reduce 25(OH)-vitamin D deficiency and the mortality associated with COVID-19 in African Americans? *J Am Coll Nutr*. 2020;39(8):694-699. doi:10.1080/07315724.2020.1789518

65. Mercola J, Grant WB, Wagner CL. Evidence regarding vitamin D and risk of COVID-19 and its severity. *Nutrients*. 2020;12(11). doi:10.3390/nut12113631

66. Benskin L. A Basic Review of the Preliminary Evidence That COVID-19 Risk and Severity is Increased in Vitamin D Deficiency. Social Science Research Network; Published 2020. Accessed March 3, 2021. https://papers.ssrn.com/abstract=3669379

67. Tan CW, Ho LP, Kalimuddin S, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). *Nutr Burbank Los Angel Cty Calif*. 2020;79-80:111017. doi:10.1016/j.nut.2020.111017

68. ProgenaBiome. A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection. Clinicaltrials.gov; Published 2021. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04344041

69. Louisiana State University Health Sciences Center in New Orleans. The LEAD COVID-19 Trial: Low-Risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04363840

70. University Hospital, Angers. COVID-19 and Vitamin D Supplementation: A Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-Risk COVID-19 Patients (CoVitTrial). Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04344041

71. ProgenaBiome. A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection. Clinicaltrials.gov; Published 2021. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04335084

72. Tameside General Hospital. Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04386044

73. University Hospital, Lille. Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04351490

74. Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. *Front Immunol*. 2020;11:1451. doi:10.3389/fimmu.2020.01712

75. World Health Organization. The world health report 2002. *Midwifery*. 2003;19(1):72-73. doi:10.1054/miw.2002.0343

76. Abdelmaksoud AA, Ghweil AA, Hassan MH, et al. Olfactory disturbances as presenting manifestation among Egyptian patients with COVID-19: possible role of zinc. *Biol Trace Elem Res*. Published online January 7, 2021;1-8. doi:10.1007/s12011-020-02546-5

77. Heller RA, Sun Q, Hackler J, et al. Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker. *Redox Biol*. 2021;38:101764. doi:10.1016/j.redox.2020.101764

78. Desai M. Coronavirus Disease 2019—Using Ascorbic Acid and Zinc Supplementation (COVIDAtoz) Research Study a Randomized, Open Label Single Center Study. Clinicaltrials.gov; Published 2021. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04342728

79. Arenz S, Hunter J, Yang G, et al. Zinc for the prevention and treatment of SARS-CoV-2 and other acute viral respiratory infections: a rapid review. *Adv Integr Med*. 2020;7(4):252-260. doi:10.1016/j.aimed.2020.07.009

80. Public Health Statement for Zinc. Department of health and human services, public health service agency for toxic substances and disease registry. 2005. Accessed March 1, 2021. https://www.cdc.gov/TSP/PHS/PHS.aspx?phsid=300&toxid=54

81. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside—the current state of research and therapeutic uses. *Nutrients*. 2020;12(6):1616. doi:10.3390/nut12061616

82. Heer CD, Sanderson DJ, Voth LS, et al. Coronavirus infection and PARP expression dysregulate the NAD metabolome: an action-abstract. *F1000Adv Integr Med* 2020;101764. doi:10.1016/j.redox.2020.101764

83. Kraus WL. PARPs and ADP-Ribosylation: 50 Years and counting. *Mol Cell*. 2015;58(6):902-910. doi:10.1016/j.molcel.2015.06.006

84. Trammell SAJ, Weidemann BJ, Chadda A, et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. *Science*. 2016;351(6283):944-948. doi:10.1126/science.1226421

85. Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. *Front Immunol*. 2020;11:1451. doi:10.3389/fimmu.2020.01712

86. Scheibye-Knudsen M. Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized
De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. *FASEB J.* 2020;34(10):13185-13193. doi:10.1096/fj.202001807

Poe FL, Corn J. N-Acetylcysteine: a potential therapeutic agent for SARS-CoV-2. *Med Hypotheses.* 2020;143:109862. doi:10.1016/j.mehy.2020.109862

Sound Pharmaceuticals, Incorporated. *A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients.* Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04483973

Mokhtari V, Afshtarjan P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses of N-acetyl cysteine. *Cell J.* 2017;19(1):11-17. doi:10.22074/cellj.2016.4872

De Benedetto F, Aceto A, Dragani B, et al. Long-term oral N-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. *Pulm Pharmacol Ther.* 2005;18(1):41-47. doi:10.1016/j.pupt.2004.09.030

Dr Oliver Van Hecke, Dr Joseph Lee. *N-Acetylcysteine: A Rapid Review of the Evidence for Effectiveness in Treating COVID-19.* The Centre for Evidence-Based Medicine. 2020. Accessed March 1, 2020. https://www.cebm.net/covid-19/n-acetylcysteine-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid-19/

Dr Baian Al-Abdulbaqi. *Effect of N-Acetylcysteine on COVID-19 Treatment.* King Saud University Medical City. 2020. Accessed March 1, 2020. https://www.isrctn.com/ISRCTN60069084

De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. *FASEB J Off Publ Fed Am Soc Exp Biol* 2020;34(10):13185-13193. doi:10.1096/fj.202001807

Robinson, Diana, MBBS FACSEP. Nutritional and non-medication supplements permitted for performance enhancement. 2020. Accessed March 1, 2020. https://cdn1.remedyc.net/campus/wp-content/uploads/2020/02/Nutritional-and-non-medication-supplements-permitted-for-performance-enhancement-2020.pdf

Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. *Nutrients.* 2016;8(3):167. doi:10.3390/nu8030167

Ross JA, Kasum CM. Dietary Flavanoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr.* 2002;22(1):19-34. doi:10.1146/annurev.nutr.22.111401.144957

Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. *Inflamm Allergy Drug Targets.* 2010;9(4):263-285. doi:10.2174/187152810793358741

Glinsky GV. Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells. *Biomedicines.* 2020;8(5):129. doi:10.3390/biomedicines8050129

Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. *Front Immunol.* 2020;11. doi:10.3389/fimmu.2020.01518

Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and pyroptosis as therapeutic targets for COVID-19. *J Immunol.* 2020;205(2):307-312. doi:10.4049/jimmunol.2000513

Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods Basel Switz.* 2017;6(10). doi:10.3390/foods6100092

Zahedipour F, Hosseini SA, Sathyapalan T, et al. Potential effects of curcumin in the treatment of COVID-19 infection. *Phytother Res PTR.* 2020;34(11):2911-2920. doi:10.1002/ptr.6738

Ferreira VH, Nazli A, Dizzell SE, Mueller K, Kaushic C. The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. *Plos One.* 2015;10(4):e0124903. doi:10.1371/journal.pone.0124903

Das S, Sarma S, Lyndem S, Singha Roy A. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. *J Biomol Struct Dyn.* 2020;1-11. doi:10.1080/07391102.2020.1763201

Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *BioMed Res Int.* 2014;2014:186864. doi:10.1155/2014/186864

Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. *J Med Chem.* 2017;60(5):1620-1637. doi:10.1021/acs.medchem.6b00975

Turmeric. NCCIH. 2020. Accessed March 3, 2021. https://www.nccih.nih.gov/health/turmeric

Reiter RJ, Ma Q, Sharma R. Treatment of Ebola and other infectious diseases: melatonin goes viral. *Melatonin Res.* 2020;3(1):43-57. doi:10.32794/mr11250047

Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. *Adv Data.* 2004;(343):1-19.

Costello RB, Lentino CV, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. *Nutr J.* 2014;13:106. doi:10.1186/1475-2891-13-106

Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodriguez-Rodriguez A, Guerrero JM. Melatonin: buffering the immune system. *Int J Mol Sci.* 2013;14(4):8638-8683. doi:10.3390/ijms14048638

Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammation some activation. *Int J Endocrinol.* 2017;2017:1835195. doi:10.1155/2017/1835195

Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A. Therapeutic algorithm for use of melatonin in patients with COVID-19. *Front Med.* 2020;7:226. doi:10.3389/fmed.2020.00226

Instituto de Investigación Hospital Universitario La Paz. *Multicenter Randomized Controlled Trial of the Efficacy of*
Melatonin in the Prophylaxis of SARS-Coronavirus-2 Infection Among High Risk Contacts. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04353128

116. Byrareddy SN, Mohan M. SARS-CoV2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Brain Behav Immun. 2020;87:120-121. doi:10.1016/j.bbi.2020.04.079

117. Rubin R. The path to the first FDA-approved cannabis-derived treatment and what comes next. JAMA. 2018;320(12): 1227-1229. doi:10.1001/jama.2018.11914

118. Wang B, Kovalchuk A, Li D, et al. In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging. 2020;12(22):22425-22444. doi:10.18632/aging.202225

119. Nichols JM, Kaplan BLF. Immune responses regulated by Cannabidiol. Cannabis Cannabinoid Res. 2020;5(1):12-31. doi:10.1089/can.2018.0073

120. Kovalchuk A, Wang B, Li D, et al. Fighting the storm: could novel anti-TNFα and anti-IL-6 C. Sativa cultivars tame cytokine storm in COVID-19? Aging. 2021;13(2):1571-1590. doi:10.18632/aging.202500

121. Stero Biotechs Announce an IP Protected Clinical Trial for COVID-19 Patients using a CBD-Steroid Treatment. Stero Biotechs, Ltd. 2020. https://www.prnewswire.com/news-releases/stero-biotechs-announce-an-ip-protected-clinical-trial-for-covid-19-patients-using-a-cbd-steroid-treatment-301043465.html

122. Crippa JA de S. Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04467918

123. Crippa JA de S. Burnout and Distress Prevention With Cannabidiol in Front-Line Health Care Workers Dealing (Bonsai Study) With COVID-19: A Randomised Controlled Trial. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04504877

124. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549-556. doi:10.1016/j.biopsych.2015.08.001

125. Alexander LEC, Bellinghausen AL, Eakin MN. What are the mechanisms underlying vaping-induced lung injury? J Clin Invest. 2020;130(6):2754-2756. doi:10.1172/JCI138644

126. Grebow J. Dietary supplement sales skyrocket during coronavirus pandemic. Nutr Outlook. 2020;23(4). Accessed March 1, 2020. https://www.nutritionaloutlook.com/view/direct-to-consumer-brand-organifi-announces-omni-channel-retail-distribution-strategy

127. Affairs O of R. Fraudulent Coronavirus Disease 2019 (COVID-19) Products. FDA; Published online March 3, 2021. Accessed March 3, 2021. https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products

128. COVID-19 FAQ. The Andrew Weil center for integrative medicine. 2021. Accessed March 3, 2020. https://integrativemedicine.arizona.edu/COVID19/FAQ.html

129. Zakay-Rones Z, Thom E, Wollan T, Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 2004;32(2):132-140. doi:10.1177/147323000403200205

130. Zakay-Rones Z, Varsano N, Zlotnik M, et al. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B panama. J Altern Complement Med N Y N. 1995;1(4):361-369. doi:10.1089/acm.1995.1.361

131. Hawkins J, Baker C, Cherry L, Dunne E. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: a meta-analysis of randomized, controlled clinical trials. Complement Ther Med. 2019;42:361-365. doi:10.1016/j.ctim.2018.12.004

132. Colloidal Silver. NCCIH. 2017. Accessed March 3, 2021. https://www.nccih.nih.gov/health/colloidal-silver

133. Commissioner O of the. Coronavirus Update: FDA and FTC Warn Seven Companies Selling Fraudulent Products that Claim to Treat or Prevent COVID-19. FDA; Published March 2020. Accessed February 24, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-update-fda-and-ftc-warn-seven-companies-selling-fraudulent-products-claim-treat-or

134. Gamaleldin MMA. Impact of Different Treatment Modalities on Immunity Against COVID-19. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04535705

135. Gomaa A. Evaluation of the Potential Therapeutic Effects of Liquorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine. Clinicaltrials.gov; Published 2020. Accessed March 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04487964

136. Lee MR. Liquorice (glycyrrhiza glabra): the journey of the sweet root from Mesopotamia to England. J R Coll Physicians Edinb. 2018;48(4):378-382. doi:10.4997/JRCPE.2018.419

137. HealthQuilt. Impact of a Proprietary Extract of Nerium Oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon. 2010;56(3):273-281. doi:10.1016/j.toxicon.2010.03.026